South Korea Biosimilar Market Size, Share, Trends and Forecast by Molecule, Indication, Manufacturing Type, and Region, 2026-2034
The South Korea biosimilar market size reached USD 626.5 Million in 2025. Looking forward, IMARC Group expects the market to reach USD 3,992.3 Million by 2034, exhibiting a growth rate (CAGR) of 22.16% during 2026-2034. The market is driven by supportive government policies and streamlined regulatory regimes enabling biosimilar access. Robust domestic R&D and GMP-ready manufacturing capacity strengthen local development and export potential. The increasing acceptance of biosimilars among clinicians, payers, and patients is further augmenting the South Korea biosimilar market share.
SOUTH KOREA BIOSIMILAR MARKET TRENDS:
Government Initiatives and Policy Support
South Korea’s government has established a structured policy framework to promote biosimilars as a means to enhance healthcare affordability and sustainability. Incentive programs encourage local manufacturers to develop biosimilar versions of high-cost biologics nearing patent expiration. Regulatory pathways have been optimized for faster, cost-effective market entry, with streamlined approval processes based on reference product comparability and clinical bridging studies. Public hospitals and insurance schemes actively include biosimilars in their formularies, enabled by reimbursement mechanisms that favor equivalent biosimilar pricing tiers. The Ministry of Food and Drug Safety (MFDS) has published clear guidelines for quality, safety, and interchangeability, helping producers align with international standards and build clinician confidence. By mandating substitution protocols and incentivizing hospital use, policy drivers ensure market penetration. Government-funded R&D grants, biocluster development programs, and public–private partnerships further support localized manufacturing capability. On December 10, 2024, South Korea granted approval to Celltrion’s denosumab biosimilars, Stavoklone and Oseni Belt, which reference Prolia and Xgeva for treating osteoporosis and cancer-related bone metastasis. These biosimilars, backed by phase 3 clinical trial results, are the first of their kind approved in the country and are expected to enhance South Korea's position in the global biosimilar market. These initiatives reduce entry barriers and foster a competitive landscape. The result is a well-coordinated policy ecosystem that propels the South Korea biosimilar market growth by making biosimilars both viable for producers and accessible to patients.
Expanding Local R&D and Domestic Manufacturing Capacity
South Korea has invested substantially in domestic biopharmaceutical infrastructure, facilitating the rise of biosimilar innovation capabilities. Leading Korean companies and universities are collaborating to develop biosimilars across therapeutic classes, such as oncology, autoimmune and endocrine, leveraging advanced bioprocessing platforms and manufacturing technology transfers. Production facilities are compliant with global Good Manufacturing Practice (GMP) standards, enabling both domestic use and export potential. Local firms are rapidly scaling capacity, adopting single-use bioreactors, intensified fermentation techniques, and automation to drive cost efficiencies and increase batch consistency. The ecosystem includes contract development and manufacturing organizations (CDMOs), analytical contract research organizations (CROs), and biosimilarity testing service providers, creating a full value chain capable of rapid development cycles. Companies increasingly build global partnerships to co-develop and co-promote biosimilars in overseas markets. On October 11, 2024, South Korea-based Dong-A ST received FDA approval for Imuldosa (ustekinumab-srlf/DMB-3115), a biosimilar referencing Johnson & Johnson's Stelara, used to treat autoimmune diseases such as Crohn's disease and psoriatic arthritis. These internal assets reduce dependency on foreign licensing and catalyze homegrown innovation. As a result, South Korea’s manufacturing readiness and integrated R&D pipelines underpin a competitive edge, ensuring market growth driven by capacity, quality, and technological capability.
SOUTH KOREA BIOSIMILAR MARKET SEGMENTATION:
IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the country and regional levels for 2026-2034. Our report has categorized the market based on molecule, indication, and manufacturing type.
Molecule Insights:
Indication Insights:
Manufacturing Type Insights:
Regional Insights:
COMPETITIVE LANDSCAPE:
The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.
KEY QUESTIONS ANSWERED IN THIS REPORT
How has the South Korea biosimilar market performed so far and how will it perform in the coming years?
What is the breakup of the South Korea biosimilar market on the basis of molecule?
What is the breakup of the South Korea biosimilar market on the basis of indication?
What is the breakup of the South Korea biosimilar market on the basis of manufacturing type?
What is the breakup of the South Korea biosimilar market on the basis of region?
What are the various stages in the value chain of the South Korea biosimilar market?
What are the key driving factors and challenges in the South Korea biosimilar?
What is the structure of the South Korea biosimilar market and who are the key players?
What is the degree of competition in the South Korea biosimilar market?
SOUTH KOREA BIOSIMILAR MARKET TRENDS:
Government Initiatives and Policy Support
South Korea’s government has established a structured policy framework to promote biosimilars as a means to enhance healthcare affordability and sustainability. Incentive programs encourage local manufacturers to develop biosimilar versions of high-cost biologics nearing patent expiration. Regulatory pathways have been optimized for faster, cost-effective market entry, with streamlined approval processes based on reference product comparability and clinical bridging studies. Public hospitals and insurance schemes actively include biosimilars in their formularies, enabled by reimbursement mechanisms that favor equivalent biosimilar pricing tiers. The Ministry of Food and Drug Safety (MFDS) has published clear guidelines for quality, safety, and interchangeability, helping producers align with international standards and build clinician confidence. By mandating substitution protocols and incentivizing hospital use, policy drivers ensure market penetration. Government-funded R&D grants, biocluster development programs, and public–private partnerships further support localized manufacturing capability. On December 10, 2024, South Korea granted approval to Celltrion’s denosumab biosimilars, Stavoklone and Oseni Belt, which reference Prolia and Xgeva for treating osteoporosis and cancer-related bone metastasis. These biosimilars, backed by phase 3 clinical trial results, are the first of their kind approved in the country and are expected to enhance South Korea's position in the global biosimilar market. These initiatives reduce entry barriers and foster a competitive landscape. The result is a well-coordinated policy ecosystem that propels the South Korea biosimilar market growth by making biosimilars both viable for producers and accessible to patients.
Expanding Local R&D and Domestic Manufacturing Capacity
South Korea has invested substantially in domestic biopharmaceutical infrastructure, facilitating the rise of biosimilar innovation capabilities. Leading Korean companies and universities are collaborating to develop biosimilars across therapeutic classes, such as oncology, autoimmune and endocrine, leveraging advanced bioprocessing platforms and manufacturing technology transfers. Production facilities are compliant with global Good Manufacturing Practice (GMP) standards, enabling both domestic use and export potential. Local firms are rapidly scaling capacity, adopting single-use bioreactors, intensified fermentation techniques, and automation to drive cost efficiencies and increase batch consistency. The ecosystem includes contract development and manufacturing organizations (CDMOs), analytical contract research organizations (CROs), and biosimilarity testing service providers, creating a full value chain capable of rapid development cycles. Companies increasingly build global partnerships to co-develop and co-promote biosimilars in overseas markets. On October 11, 2024, South Korea-based Dong-A ST received FDA approval for Imuldosa (ustekinumab-srlf/DMB-3115), a biosimilar referencing Johnson & Johnson's Stelara, used to treat autoimmune diseases such as Crohn's disease and psoriatic arthritis. These internal assets reduce dependency on foreign licensing and catalyze homegrown innovation. As a result, South Korea’s manufacturing readiness and integrated R&D pipelines underpin a competitive edge, ensuring market growth driven by capacity, quality, and technological capability.
SOUTH KOREA BIOSIMILAR MARKET SEGMENTATION:
IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the country and regional levels for 2026-2034. Our report has categorized the market based on molecule, indication, and manufacturing type.
Molecule Insights:
- Infliximab
- Insulin Glargine
- Epoetin Alfa
- Etanercept
- Filgrastim
- Somatropin
- Rituximab
- Follitropin Alfa
- Adalimumab
- Pegfilgrastim
- Trastuzumab
- Bevacizumab
- Others
Indication Insights:
- Auto-Immune Diseases
- Blood Disorder
- Diabetes
- Oncology
- Growth Deficiency
- Female Infertility
- Others
Manufacturing Type Insights:
- In-house Manufacturing
- Contract Manufacturing
Regional Insights:
- Seoul Capital Area
- Yeongnam (Southeastern Region)
- Honam (Southwestern Region)
- Hoseo (Central Region)
- Others
COMPETITIVE LANDSCAPE:
The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.
KEY QUESTIONS ANSWERED IN THIS REPORT
How has the South Korea biosimilar market performed so far and how will it perform in the coming years?
What is the breakup of the South Korea biosimilar market on the basis of molecule?
What is the breakup of the South Korea biosimilar market on the basis of indication?
What is the breakup of the South Korea biosimilar market on the basis of manufacturing type?
What is the breakup of the South Korea biosimilar market on the basis of region?
What are the various stages in the value chain of the South Korea biosimilar market?
What are the key driving factors and challenges in the South Korea biosimilar?
What is the structure of the South Korea biosimilar market and who are the key players?
What is the degree of competition in the South Korea biosimilar market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1.1 Objectives of the Study
2.1.2 Stakeholders
2.1.3 Data Sources
2.1.3.1 Primary Sources
2.1.3.2 Secondary Sources
2.1.4 Market Estimation
2.1.4.1 Bottom-Up Approach
2.1.4.2 Top-Down Approach
2.1.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 SOUTH KOREA BIOSIMILAR MARKET - INTRODUCTION
4.1.1 Overview
4.1.2 Market Dynamics
4.1.3 Industry Trends
4.1.4 Competitive Intelligence
5 SOUTH KOREA BIOSIMILAR MARKET LANDSCAPE
5.1.1 Historical and Current Market Trends (?2020-2025?)
5.1.2 Market Forecast (?2026-2034?)
6 SOUTH KOREA BIOSIMILAR MARKET - BREAKUP BY MOLECULE
6.1 Infliximab
6.1.1 Overview
6.1.2 Historical and Current Market Trends (?2020-2025?)
6.1.3 Market Forecast (?2026-2034?)
6.2 Insulin Glargine
6.2.1 Overview
6.2.2 Historical and Current Market Trends (?2020-2025?)
6.2.3 Market Forecast (?2026-2034?)
6.3 Epoetin Alfa
6.3.1 Overview
6.3.2 Historical and Current Market Trends (?2020-2025?)
6.3.3 Market Forecast (?2026-2034?)
6.4 Etanercept
6.4.1 Overview
6.4.2 Historical and Current Market Trends (?2020-2025?)
6.4.3 Market Forecast (?2026-2034?)
6.5 Filgrastim
6.5.1 Overview
6.5.2 Historical and Current Market Trends (?2020-2025?)
6.5.3 Market Forecast (?2026-2034?)
6.6 Somatropin
6.6.1 Overview
6.6.2 Historical and Current Market Trends (?2020-2025?)
6.6.3 Market Forecast (?2026-2034?)
6.7 Rituximab
6.7.1 Overview
6.7.2 Historical and Current Market Trends (?2020-2025?)
6.7.3 Market Forecast (?2026-2034?)
6.8 Follitropin Alfa
6.8.1 Overview
6.8.2 Historical and Current Market Trends (?2020-2025?)
6.8.3 Market Forecast (?2026-2034?)
6.9 Adalimumab
6.9.1 Overview
6.9.2 Historical and Current Market Trends (?2020-2025?)
6.9.3 Market Forecast (?2026-2034?)
6.10 Pegfilgrastim
6.10.1 Overview
6.10.2 Historical and Current Market Trends (?2020-2025?)
6.10.3 Market Forecast (?2026-2034?)
6.11 Trastuzumab
6.11.1 Overview
6.11.2 Historical and Current Market Trends (?2020-2025?)
6.11.3 Market Forecast (?2026-2034?)
6.12 Bevacizumab
6.12.1 Overview
6.12.2 Historical and Current Market Trends (?2020-2025?)
6.12.3 Market Forecast (?2026-2034?)
6.13 Others
6.13.1 Historical and Current Market Trends (?2020-2025?)
6.13.2 Market Forecast (?2026-2034?)
7 SOUTH KOREA BIOSIMILAR MARKET - BREAKUP BY INDICATION
7.1 Auto-Immune Diseases
7.1.1 Overview
7.1.2 Historical and Current Market Trends (?2020-2025?)
7.1.3 Market Forecast (?2026-2034?)
7.2 Blood Disorder
7.2.1 Overview
7.2.2 Historical and Current Market Trends (?2020-2025?)
7.2.3 Market Forecast (?2026-2034?)
7.3 Diabetes
7.3.1 Overview
7.3.2 Historical and Current Market Trends (?2020-2025?)
7.3.3 Market Forecast (?2026-2034?)
7.4 Oncology
7.4.1 Overview
7.4.2 Historical and Current Market Trends (?2020-2025?)
7.4.3 Market Forecast (?2026-2034?)
7.5 Growth Deficiency
7.5.1 Overview
7.5.2 Historical and Current Market Trends (?2020-2025?)
7.5.3 Market Forecast (?2026-2034?)
7.6 Female Infertility
7.6.1 Overview
7.6.2 Historical and Current Market Trends (?2020-2025?)
7.6.3 Market Forecast (?2026-2034?)
7.7 Others
7.7.1 Historical and Current Market Trends (?2020-2025?)
7.7.2 Market Forecast (?2026-2034?)
8 SOUTH KOREA BIOSIMILAR MARKET - BREAKUP BY MANUFACTURING TYPE
8.1 In-house Manufacturing
8.1.1 Overview
8.1.2 Historical and Current Market Trends (?2020-2025?)
8.1.3 Market Forecast (?2026-2034?)
8.2 Contract Manufacturing
8.2.1 Overview
8.2.2 Historical and Current Market Trends (?2020-2025?)
8.2.3 Market Forecast (?2026-2034?)
9 SOUTH KOREA BIOSIMILAR MARKET – BREAKUP BY REGION
9.1 Seoul Capital Area
9.1.1 Overview
9.1.2 Historical and Current Market Trends (?2020-2025?)
9.1.3 Market Breakup by Molecule
9.1.4 Market Breakup by Indication
9.1.5 Market Breakup by Manufacturing Type
9.1.6 Key Players
9.1.7 Market Forecast (?2026-2034?)
9.2 Yeongnam (Southeastern Region)
9.2.1 Overview
9.2.2 Historical and Current Market Trends (?2020-2025?)
9.2.3 Market Breakup by Molecule
9.2.4 Market Breakup by Indication
9.2.5 Market Breakup by Manufacturing Type
9.2.6 Key Players
9.2.7 Market Forecast (?2026-2034?)
9.3 Honam (Southwestern Region)
9.3.1 Overview
9.3.2 Historical and Current Market Trends (?2020-2025?)
9.3.3 Market Breakup by Molecule
9.3.4 Market Breakup by Indication
9.3.5 Market Breakup by Manufacturing Type
9.3.6 Key Players
9.3.7 Market Forecast (?2026-2034?)
9.4 Hoseo (Central Region)
9.4.1 Overview
9.4.2 Historical and Current Market Trends (?2020-2025?)
9.4.3 Market Breakup by Molecule
9.4.4 Market Breakup by Indication
9.4.5 Market Breakup by Manufacturing Type
9.4.6 Key Players
9.4.7 Market Forecast (?2026-2034?)
9.5 Others
9.5.1 Historical and Current Market Trends (?2020-2025?)
9.5.2 Market Forecast (?2026-2034?)
10 SOUTH KOREA BIOSIMILAR MARKET – COMPETITIVE LANDSCAPE
10.1 Overview
10.2 Market Structure
10.3 Market Player Positioning
10.4 Top Winning Strategies
10.5 Competitive Dashboard
10.6 Company Evaluation Quadrant
11 PROFILES OF KEY PLAYERS
11.1 Company A
11.1.1 Business Overview
11.1.2 Products Offered
11.1.3 Business Strategies
11.1.4 SWOT Analysis
11.1.5 Major News and Events
11.2 Company B
11.2.1 Business Overview
11.2.2 Products Offered
11.2.3 Business Strategies
11.2.4 SWOT Analysis
11.2.5 Major News and Events
11.3 Company C
11.3.1 Business Overview
11.3.2 Products Offered
11.3.3 Business Strategies
11.3.4 SWOT Analysis
11.3.5 Major News and Events
11.4 Company D
11.4.1 Business Overview
11.4.2 Products Offered
11.4.3 Business Strategies
11.4.4 SWOT Analysis
11.4.5 Major News and Events
11.5 Company E
11.5.1 Business Overview
11.5.2 Products Offered
11.5.3 Business Strategies
11.5.4 SWOT Analysis
11.5.5 Major News and Events
12 SOUTH KOREA BIOSIMILAR MARKET - INDUSTRY ANALYSIS
12.1 Drivers, Restraints, and Opportunities
12.1.1 Overview
12.1.2 Drivers
12.1.3 Restraints
12.1.4 Opportunities
12.2 Porters Five Forces Analysis
12.2.1 Overview
12.2.2 Bargaining Power of Buyers
12.2.3 Bargaining Power of Suppliers
12.2.4 Degree of Competition
12.2.5 Threat of New Entrants
12.2.6 Threat of Substitutes
12.3 Value Chain Analysis
13 APPENDIX
2 SCOPE AND METHODOLOGY
2.1.1 Objectives of the Study
2.1.2 Stakeholders
2.1.3 Data Sources
2.1.3.1 Primary Sources
2.1.3.2 Secondary Sources
2.1.4 Market Estimation
2.1.4.1 Bottom-Up Approach
2.1.4.2 Top-Down Approach
2.1.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 SOUTH KOREA BIOSIMILAR MARKET - INTRODUCTION
4.1.1 Overview
4.1.2 Market Dynamics
4.1.3 Industry Trends
4.1.4 Competitive Intelligence
5 SOUTH KOREA BIOSIMILAR MARKET LANDSCAPE
5.1.1 Historical and Current Market Trends (?2020-2025?)
5.1.2 Market Forecast (?2026-2034?)
6 SOUTH KOREA BIOSIMILAR MARKET - BREAKUP BY MOLECULE
6.1 Infliximab
6.1.1 Overview
6.1.2 Historical and Current Market Trends (?2020-2025?)
6.1.3 Market Forecast (?2026-2034?)
6.2 Insulin Glargine
6.2.1 Overview
6.2.2 Historical and Current Market Trends (?2020-2025?)
6.2.3 Market Forecast (?2026-2034?)
6.3 Epoetin Alfa
6.3.1 Overview
6.3.2 Historical and Current Market Trends (?2020-2025?)
6.3.3 Market Forecast (?2026-2034?)
6.4 Etanercept
6.4.1 Overview
6.4.2 Historical and Current Market Trends (?2020-2025?)
6.4.3 Market Forecast (?2026-2034?)
6.5 Filgrastim
6.5.1 Overview
6.5.2 Historical and Current Market Trends (?2020-2025?)
6.5.3 Market Forecast (?2026-2034?)
6.6 Somatropin
6.6.1 Overview
6.6.2 Historical and Current Market Trends (?2020-2025?)
6.6.3 Market Forecast (?2026-2034?)
6.7 Rituximab
6.7.1 Overview
6.7.2 Historical and Current Market Trends (?2020-2025?)
6.7.3 Market Forecast (?2026-2034?)
6.8 Follitropin Alfa
6.8.1 Overview
6.8.2 Historical and Current Market Trends (?2020-2025?)
6.8.3 Market Forecast (?2026-2034?)
6.9 Adalimumab
6.9.1 Overview
6.9.2 Historical and Current Market Trends (?2020-2025?)
6.9.3 Market Forecast (?2026-2034?)
6.10 Pegfilgrastim
6.10.1 Overview
6.10.2 Historical and Current Market Trends (?2020-2025?)
6.10.3 Market Forecast (?2026-2034?)
6.11 Trastuzumab
6.11.1 Overview
6.11.2 Historical and Current Market Trends (?2020-2025?)
6.11.3 Market Forecast (?2026-2034?)
6.12 Bevacizumab
6.12.1 Overview
6.12.2 Historical and Current Market Trends (?2020-2025?)
6.12.3 Market Forecast (?2026-2034?)
6.13 Others
6.13.1 Historical and Current Market Trends (?2020-2025?)
6.13.2 Market Forecast (?2026-2034?)
7 SOUTH KOREA BIOSIMILAR MARKET - BREAKUP BY INDICATION
7.1 Auto-Immune Diseases
7.1.1 Overview
7.1.2 Historical and Current Market Trends (?2020-2025?)
7.1.3 Market Forecast (?2026-2034?)
7.2 Blood Disorder
7.2.1 Overview
7.2.2 Historical and Current Market Trends (?2020-2025?)
7.2.3 Market Forecast (?2026-2034?)
7.3 Diabetes
7.3.1 Overview
7.3.2 Historical and Current Market Trends (?2020-2025?)
7.3.3 Market Forecast (?2026-2034?)
7.4 Oncology
7.4.1 Overview
7.4.2 Historical and Current Market Trends (?2020-2025?)
7.4.3 Market Forecast (?2026-2034?)
7.5 Growth Deficiency
7.5.1 Overview
7.5.2 Historical and Current Market Trends (?2020-2025?)
7.5.3 Market Forecast (?2026-2034?)
7.6 Female Infertility
7.6.1 Overview
7.6.2 Historical and Current Market Trends (?2020-2025?)
7.6.3 Market Forecast (?2026-2034?)
7.7 Others
7.7.1 Historical and Current Market Trends (?2020-2025?)
7.7.2 Market Forecast (?2026-2034?)
8 SOUTH KOREA BIOSIMILAR MARKET - BREAKUP BY MANUFACTURING TYPE
8.1 In-house Manufacturing
8.1.1 Overview
8.1.2 Historical and Current Market Trends (?2020-2025?)
8.1.3 Market Forecast (?2026-2034?)
8.2 Contract Manufacturing
8.2.1 Overview
8.2.2 Historical and Current Market Trends (?2020-2025?)
8.2.3 Market Forecast (?2026-2034?)
9 SOUTH KOREA BIOSIMILAR MARKET – BREAKUP BY REGION
9.1 Seoul Capital Area
9.1.1 Overview
9.1.2 Historical and Current Market Trends (?2020-2025?)
9.1.3 Market Breakup by Molecule
9.1.4 Market Breakup by Indication
9.1.5 Market Breakup by Manufacturing Type
9.1.6 Key Players
9.1.7 Market Forecast (?2026-2034?)
9.2 Yeongnam (Southeastern Region)
9.2.1 Overview
9.2.2 Historical and Current Market Trends (?2020-2025?)
9.2.3 Market Breakup by Molecule
9.2.4 Market Breakup by Indication
9.2.5 Market Breakup by Manufacturing Type
9.2.6 Key Players
9.2.7 Market Forecast (?2026-2034?)
9.3 Honam (Southwestern Region)
9.3.1 Overview
9.3.2 Historical and Current Market Trends (?2020-2025?)
9.3.3 Market Breakup by Molecule
9.3.4 Market Breakup by Indication
9.3.5 Market Breakup by Manufacturing Type
9.3.6 Key Players
9.3.7 Market Forecast (?2026-2034?)
9.4 Hoseo (Central Region)
9.4.1 Overview
9.4.2 Historical and Current Market Trends (?2020-2025?)
9.4.3 Market Breakup by Molecule
9.4.4 Market Breakup by Indication
9.4.5 Market Breakup by Manufacturing Type
9.4.6 Key Players
9.4.7 Market Forecast (?2026-2034?)
9.5 Others
9.5.1 Historical and Current Market Trends (?2020-2025?)
9.5.2 Market Forecast (?2026-2034?)
10 SOUTH KOREA BIOSIMILAR MARKET – COMPETITIVE LANDSCAPE
10.1 Overview
10.2 Market Structure
10.3 Market Player Positioning
10.4 Top Winning Strategies
10.5 Competitive Dashboard
10.6 Company Evaluation Quadrant
11 PROFILES OF KEY PLAYERS
11.1 Company A
11.1.1 Business Overview
11.1.2 Products Offered
11.1.3 Business Strategies
11.1.4 SWOT Analysis
11.1.5 Major News and Events
11.2 Company B
11.2.1 Business Overview
11.2.2 Products Offered
11.2.3 Business Strategies
11.2.4 SWOT Analysis
11.2.5 Major News and Events
11.3 Company C
11.3.1 Business Overview
11.3.2 Products Offered
11.3.3 Business Strategies
11.3.4 SWOT Analysis
11.3.5 Major News and Events
11.4 Company D
11.4.1 Business Overview
11.4.2 Products Offered
11.4.3 Business Strategies
11.4.4 SWOT Analysis
11.4.5 Major News and Events
11.5 Company E
11.5.1 Business Overview
11.5.2 Products Offered
11.5.3 Business Strategies
11.5.4 SWOT Analysis
11.5.5 Major News and Events
12 SOUTH KOREA BIOSIMILAR MARKET - INDUSTRY ANALYSIS
12.1 Drivers, Restraints, and Opportunities
12.1.1 Overview
12.1.2 Drivers
12.1.3 Restraints
12.1.4 Opportunities
12.2 Porters Five Forces Analysis
12.2.1 Overview
12.2.2 Bargaining Power of Buyers
12.2.3 Bargaining Power of Suppliers
12.2.4 Degree of Competition
12.2.5 Threat of New Entrants
12.2.6 Threat of Substitutes
12.3 Value Chain Analysis
13 APPENDIX
